Literature DB >> 18950731

VHL loss of function and its impact on oncogenic signaling networks in clear cell renal cell carcinoma.

W Marston Linehan1, Jeffrey S Rubin, Donald P Bottaro.   

Abstract

Loss of von Hippel-Lindau tumor suppressor gene function occurs in familial and most sporadic clear cell renal cell carcinoma, resulting in the aberrant expression of genes that control cell proliferation, metabolism, invasion and angiogenesis. The molecular mechanisms by which loss of function leads to tumorigenesis are not yet fully defined. The von Hippel-Lindau gene product is part of an ubiquitin ligase complex that targets hypoxia inducible factors for polyubiquitination and proteasomal degradation, linking hypoxia response genes to renal cell carcinoma oncogenesis. Loss von Hippel-Lindau gene function also promotes cell invasiveness in response to hepatocyte growth factor, an important regulator of kidney development and renal homeostasis. Increased cell invasiveness is mediated by another ubiquitin ligase target with relevance to the molecular pathogenesis of renal cell carcinoma: beta-catenin. This discovery and other recent insights into kidney cancer oncogenesis implicate convergent developmental and homeostatic signaling pathways in tumorigenesis, tumor invasiveness and metastasis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18950731      PMCID: PMC2684867          DOI: 10.1016/j.biocel.2008.09.024

Source DB:  PubMed          Journal:  Int J Biochem Cell Biol        ISSN: 1357-2725            Impact factor:   5.085


  22 in total

1.  Metanephrogenic mesenchyme-to-epithelium transition induces profound expression changes of ion channels.

Authors:  S M Huber; G S Braun; S Segerer; R W Veh; M F Horster
Journal:  Am J Physiol Renal Physiol       Date:  2000-07

Review 2.  Wnt/beta-catenin signaling in development and disease.

Authors:  Hans Clevers
Journal:  Cell       Date:  2006-11-03       Impact factor: 41.582

3.  Interaction between beta-catenin and HIF-1 promotes cellular adaptation to hypoxia.

Authors:  Abderrahmane Kaidi; Ann Caroline Williams; Christos Paraskeva
Journal:  Nat Cell Biol       Date:  2007-01-14       Impact factor: 28.824

Review 4.  The role of VHL in the regulation of E-cadherin: a new connection in an old pathway.

Authors:  Ryan C Russell; Michael Ohh
Journal:  Cell Cycle       Date:  2007-01-05       Impact factor: 4.534

5.  Wnt antagonist family genes as biomarkers for diagnosis, staging, and prognosis of renal cell carcinoma using tumor and serum DNA.

Authors:  Shinji Urakami; Hiroaki Shiina; Hideki Enokida; Hiroshi Hirata; Ken Kawamoto; Toshifumi Kawakami; Nobuyuki Kikuno; Yuichiro Tanaka; Shahana Majid; Masayuki Nakagawa; Mikio Igawa; Rajvir Dahiya
Journal:  Clin Cancer Res       Date:  2006-12-01       Impact factor: 12.531

6.  Frequent loss of SFRP1 expression in multiple human solid tumours: association with aberrant promoter methylation in renal cell carcinoma.

Authors:  E Dahl; F Wiesmann; M Woenckhaus; R Stoehr; P J Wild; J Veeck; R Knüchel; E Klopocki; G Sauter; R Simon; W F Wieland; B Walter; S Denzinger; A Hartmann; C G Hammerschmied
Journal:  Oncogene       Date:  2007-03-12       Impact factor: 9.867

Review 7.  Hepatocyte growth factor: renotropic role and potential therapeutics for renal diseases.

Authors:  K Matsumoto; T Nakamura
Journal:  Kidney Int       Date:  2001-06       Impact factor: 10.612

8.  Activation of hepatocyte growth factor (HGF) by endogenous HGF activator is required for metanephric kidney morphogenesis in vitro.

Authors:  J van Adelsberg; S Sehgal; A Kukes; C Brady; J Barasch; J Yang; Y Huan
Journal:  J Biol Chem       Date:  2000-10-13       Impact factor: 5.157

Review 9.  Wnt signaling in renal cancer.

Authors:  Héctor Guillén-Ahlers
Journal:  Curr Drug Targets       Date:  2008-07       Impact factor: 3.465

10.  Secreted frizzled-related protein 1 loss contributes to tumor phenotype of clear cell renal cell carcinoma.

Authors:  Michelle L Gumz; Hongzhi Zou; Pamela A Kreinest; April C Childs; Leandra S Belmonte; Shauna N LeGrand; Kevin J Wu; Bruce A Luxon; Mala Sinha; Alexander S Parker; L-Z Sun; David A Ahlquist; Christopher G Wood; John A Copland
Journal:  Clin Cancer Res       Date:  2007-08-15       Impact factor: 12.531

View more
  27 in total

Review 1.  The RPTEC/TERT1 Cell Line as an Improved Tool for In Vitro Nephrotoxicity Assessments.

Authors:  Bridget R Simon-Friedt; Mark J Wilson; Diane A Blake; Haini Yu; Yasmin Eriksson; Jeffrey K Wickliffe
Journal:  Biol Trace Elem Res       Date:  2015-04-19       Impact factor: 3.738

Review 2.  Signaling pathways in renal cell carcinoma.

Authors:  Gowrishankar Banumathy; Paul Cairns
Journal:  Cancer Biol Ther       Date:  2010-10-01       Impact factor: 4.742

3.  MicroRNA-1826 directly targets beta-catenin (CTNNB1) and MEK1 (MAP2K1) in VHL-inactivated renal cancer.

Authors:  Hiroshi Hirata; Yuji Hinoda; Koji Ueno; Koichi Nakajima; Nobuhisa Ishii; Rajvir Dahiya
Journal:  Carcinogenesis       Date:  2011-12-17       Impact factor: 4.944

Review 4.  Resistance to Targeted Therapies in Renal Cancer: The Importance of Changing the Mechanism of Action.

Authors:  I Duran; J Lambea; P Maroto; J L González-Larriba; Luis Flores; S Granados-Principal; M Graupera; B Sáez; A Vivancos; O Casanovas
Journal:  Target Oncol       Date:  2017-02       Impact factor: 4.493

5.  Mutant thyroid hormone receptors (TRs) isolated from distinct cancer types display distinct target gene specificities: a unique regulatory repertoire associated with two renal clear cell carcinomas.

Authors:  Meghan D Rosen; Ivan H Chan; Martin L Privalsky
Journal:  Mol Endocrinol       Date:  2011-05-26

Review 6.  Misdiagnosis of clear cell renal cell carcinoma.

Authors:  Vladimir A Valera; Maria J Merino
Journal:  Nat Rev Urol       Date:  2011-05-17       Impact factor: 14.432

Review 7.  A Comprehensive Review of Pediatric Tumors and Associated Cancer Predisposition Syndromes.

Authors:  Sarah Scollon; Amanda Knoth Anglin; Martha Thomas; Joyce T Turner; Kami Wolfe Schneider
Journal:  J Genet Couns       Date:  2017-03-29       Impact factor: 2.537

Review 8.  Von Hippel-Lindau disease (VHL): a need for a murine model with retinal hemangioblastoma.

Authors:  Stanley Park; Chi-Chao Chan
Journal:  Histol Histopathol       Date:  2012-08       Impact factor: 2.303

9.  Suppression of MMP-9 activity by NDRG2 expression inhibits clear cell renal cell carcinoma invasion.

Authors:  Jian-Jun Ma; Ling-Min Kong; Cheng-Gong Liao; Xue Jiang; Yong Wang; Ting-Yi Bao
Journal:  Med Oncol       Date:  2012-06-13       Impact factor: 3.064

Review 10.  Epigenomics of clear cell renal cell carcinoma: mechanisms and potential use in molecular pathology.

Authors:  Tianying Xing; Huiying He
Journal:  Chin J Cancer Res       Date:  2016-02       Impact factor: 5.087

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.